Unibest
← Back to patent-cliff list

B-007A

Tier C — Watch / trade

B-007A

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Updating

Indications (approved):Nephropathy

Regional status

US
-
EU
-
China
Phase II
2024-12-31
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of B-007A?

Approved indications include: Nephropathy.

When does the B-007A patent expire?

No public expiry year is available for B-007A yet; this page updates once verified.

How do I get a quote for B-007A intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-01